On this Monday before Super Tuesday the insulin pump world received two pieces of news, one good, one not so good. On the positive side Tandem announced the FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller. Per a company issued press release;
“Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC). This is the second system to receive iAGC designation by the FDA, following the Company’s clearance . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.